A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
C4 Therapeutics, Inc.
Study ID
NCT07280013
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Multiple Myeloma (MM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemsidomide — DRUG
    IKZF1/3 degrader
  • Elranatamab — BIOLOGICAL
    • BCMA-CD3 bispecific antibody

Study Details

The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.

Key Dates

First listed
Dec 12, 2025
Start date
Feb 6, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Non-randomized cemsidomide (tablet) plus elranatamab (subcutaneous injection)

Primary Outcome Measure

Safety and tolerability of cemsidomide in combination with elranatamab [ Time Frame: Cycle 1 approximately 28 days ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer CenterGilbertArizona85234-
UC Davis Comprehensive Cancer CenterSacramentoCalifornia95817-
UCLA Health, Jonsson Comprehensive Cancer CenterSanta MonicaCalifornia90404-
University of FloridaGainesvilleFlorida32610-
University of MiamiMiamiFlorida33136-
Winship Cancer Institute, Emory UniversityAtlantaGeorgia30322-
Loyola University Medical CenterMaywoodIllinois60153-
Indiana UniversityIndianapolisIndiana46202-
Norton Cancer Institute St. MatthewsLouisvilleKentucky40207-
University of Maryland Greenbaum Comprehensive Cancer CenterBaltimoreMaryland21201-
START MidwestGrand RapidsMichigan49546-
University of NebraskaOmahaNebraska68105-
Dartmouth-Hitchcock Medical CenterLebanonNew Hampshire03756-
Perlmutter Cancer Center at NYU Langone HospitalBrooklynNew York11203-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10021-
Duke Cancer CenterDurhamNorth Carolina27710-
Ohio State University Comprehensive Cancer CenterColumbusOhio43210-
Baylor University Medical CenterDallasTexas75246-
Houston Methodist HospitalHoustonTexas77030-
Huntsman Cancer Institute, University of UtahSalt Lake CityUtah84112-

Find similar trials in Gilbert, AZ

By research site
Banner MD Anderson Cancer Center· Gilbert, AZUC Davis Comprehensive Cancer Center· Sacramento, CAUCLA Health, Jonsson Comprehensive Cancer Center· Santa Monica, CAUniversity of Florida· Gainesville, FLUniversity of Miami· Miami, FLWinship Cancer Institute, Emory University· Atlanta, GA

Related Studies